Abivax SA Sponsored ADR $ABVX Shares Sold by Apis Capital Advisors LLC

Apis Capital Advisors LLC lowered its holdings in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) by 15.6% in the fourth quarter, HoldingsChannel.com reports. The fund owned 89,000 shares of the company’s stock after selling 16,400 shares during the quarter. Abivax comprises about 2.1% of Apis Capital Advisors LLC’s investment portfolio, making the stock its 18th biggest holding. Apis Capital Advisors LLC’s holdings in Abivax were worth $12,002,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. TCG Crossover Management LLC raised its position in Abivax by 17.4% during the third quarter. TCG Crossover Management LLC now owns 7,111,596 shares of the company’s stock worth $603,774,000 after acquiring an additional 1,055,000 shares during the last quarter. UBS Group AG raised its position in Abivax by 2,561.0% during the third quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock worth $378,761,000 after acquiring an additional 4,293,606 shares during the last quarter. Darwin Global Management Ltd. raised its position in Abivax by 0.4% during the fourth quarter. Darwin Global Management Ltd. now owns 3,178,501 shares of the company’s stock worth $439,714,000 after acquiring an additional 14,000 shares during the last quarter. Morgan Stanley raised its position in Abivax by 114.3% during the fourth quarter. Morgan Stanley now owns 3,151,994 shares of the company’s stock worth $425,062,000 after acquiring an additional 1,681,277 shares during the last quarter. Finally, Paradigm Biocapital Advisors LP acquired a new position in Abivax during the third quarter worth about $132,800,000. Institutional investors and hedge funds own 47.91% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on ABVX shares. Citizens Jmp lifted their target price on shares of Abivax from $131.00 to $187.00 and gave the stock a “market outperform” rating in a research report on Tuesday, June 2nd. Wedbush upgraded shares of Abivax from an “underperform” rating to a “neutral” rating and cut their target price for the stock from $110.00 to $90.00 in a research report on Tuesday, June 2nd. Barclays lifted their target price on shares of Abivax from $142.00 to $148.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 24th. Wall Street Zen upgraded shares of Abivax from a “sell” rating to a “hold” rating in a report on Saturday, May 23rd. Finally, Truist Financial lowered their price target on shares of Abivax from $140.00 to $135.00 and set a “buy” rating for the company in a report on Tuesday, June 2nd. Twelve research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Abivax currently has an average rating of “Moderate Buy” and an average price target of $130.08.

Abivax Price Performance

Shares of NASDAQ ABVX opened at $100.15 on Thursday. The company has a market cap of $7.99 billion, a PE ratio of -19.22 and a beta of 0.69. Abivax SA Sponsored ADR has a 12 month low of $5.69 and a 12 month high of $148.83. The company has a 50-day simple moving average of $114.81 and a 200-day simple moving average of $118.49.

Abivax (NASDAQ:ABVX) last released its earnings results on Friday, May 22nd. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.23. The company had revenue of $1.56 million during the quarter, compared to analysts’ expectations of $0.40 million. On average, analysts anticipate that Abivax SA Sponsored ADR will post -3.4 EPS for the current year.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.